Gene therapy strategies using engineered stem cells for treating gynecologic and breast cancer patients (Review)
- Authors:
- Ye-Seul Kim
- Kyung-A Hwang
- Ryeo-Eun Go
- Cho-Won Kim
- Kyung-Chul Choi
-
Affiliations: Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea - Published online on: March 10, 2015 https://doi.org/10.3892/or.2015.3846
- Pages: 2107-2112
This article is mentioned in:
Abstract
 |
|
Saukkonen K and Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 4:683–696. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Evoy D, Hirschowitz EA, Naama HA, Li XK, Crystal RG, Daly JM and Lieberman MD: In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res. 69:226–231. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, et al: In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57:461–465. 1997.PubMed/NCBI | |
|
Li Z, Shanmugam N, Katayose D, Huber B, Srivastava S, Cowan K and Seth P: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 4:113–117. 1997.PubMed/NCBI | |
|
Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 13:1663–1670. 1995.PubMed/NCBI | |
|
Castillo-Rodríguez RA, Arango-Rodríguez ML, Escobedo L, Hernandez-Baltazar D, Gompel A, Forgez P and Martínez-Fong D: Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic Mice. PLoS One. 9:e971512014. View Article : Google Scholar : PubMed/NCBI | |
|
Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, et al: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62:4968–4976. 2002.PubMed/NCBI | |
|
Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF and Kerr DJ: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8:1547–1554. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs C, Mitchell EP and Hoff PM: Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 32:491–503. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jaenisch R and Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 132:567–582. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al: Embryonic stem cell lines derived from human blastocysts. Science. 282:1145–1147. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Gavrilov S, Papaioannou VE and Landry DW: Alternative strategies for the derivation of human embryonic stem cell lines and the role of dead embryos. Curr Stem Cell Res Ther. 4:81–86. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, et al: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L and Zhang X: Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma Model. Cell Res. 18:500–507. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Brignier AC and Gewirtz AM: Embryonic and adult stem cell therapy. J Allergy Clin Immunol. 125(Suppl 2): S336–S344. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Aboody KS, Najbauer J and Danks MK: Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM, et al: Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 12:5550–5556. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, et al: Development of a tumor-selective approach to treat metastatic cancer. PLoS One. 1:e232006. View Article : Google Scholar : PubMed/NCBI | |
|
Fodde R: Stem cells and metastatic cancer: Fatal attraction? PLoS Med. 3:e4822006. View Article : Google Scholar : PubMed/NCBI | |
|
Muller FJ, Snyder EY and Loring JF: Gene therapy: can neural stem cells deliver? Nat Rev Neurosci. 7:75–84. 2006. View Article : Google Scholar | |
|
Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO and Aboody KS: Intravascular delivery of neural stem cell lines to target intra-cranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther. 14:1777–1785. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J, et al: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 15:4925–4934. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, Kim SU and Aboody KS: Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res. 6:1819–1829. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yi BR, Hwang KA, Aboody KS, Jeung EB, Kim SU and Choi KC: Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft Models. Stem Cell Res. 12:36–48. 2014. View Article : Google Scholar | |
|
Kim SU: Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 7:130–140. 2011. View Article : Google Scholar | |
|
Dietrich J, Imitola J and Kesari S: Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol. 5:393–404. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Auersperg N: Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis? Gynecol Oncol. 130:246–251. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K and Tanaka M: Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer. Cancer Sci. 100:722–729. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fu W, Lan H, Liang S, Gao T and Ren D: Suicide gene/prodrug therapy using salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2′-deoxyriboside in murine mammary carcinoma 4T1 Model. Cancer Sci. 99:1172–1179. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: Tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M and Forni G: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 154:5302–5312. 1995.PubMed/NCBI | |
|
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The ‘bystander effect’: Tumor regression when a fraction of the tumor Mass is genetically Modified. Cancer Res. 53:5274–5283. 1993.PubMed/NCBI | |
|
Jiang J, Wei D, Sun L, Wang Y, Wu X, Li Y, Fang Z, Shang H and Wei Z: A preliminary study on the construction of double suicide gene delivery vectors by mesenchymal stem cells and the in vitro inhibitory effects on SKOV3 cells. Oncol Rep. 31:781–787. 2014. | |
|
Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M and Marini FC: Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 15:20–32. 2013. View Article : Google Scholar : | |
|
Engel JB, Keller G, Schally AV, Nagy A, Chism DD and Halmos G: Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril. 83(Suppl 1): S1125–S1133. 2005. View Article : Google Scholar | |
|
Secord AA, Havrilesky LJ, O’malley DM, Bae-Jump V, Fleming ND, Broadwater G, Cohn DE and Gehrig PA: A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol. 114:442–447. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A and Oliver T: Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group: Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol. 101:158–167. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS and Rader JS: Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol. 112:553–557. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bruzzone M, Miglietta L, Franzone P, Gadducci A and Boccardo F: Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III–IV endometrial cancer patients. Gynecol Oncol. 93:345–352. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA and Bang JH: Production of immortalized human neural crest stem cells. Methods Mol Biol. 198:55–65. 2002.PubMed/NCBI | |
|
Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res. 31:2853–2861. 2011.PubMed/NCBI | |
|
Kim SU: Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology. 24:159–171. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jung S, Yi L, Kim J, Jeong D, Oh T, Kim CH, Kim CJ, Shin J, An S and Lee MS: The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells. 31:405–411. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Francis SA and Katz ML: The HPV vaccine: A comparison of focus groups conducted in South Africa and Ohio Appalachia. Matern Child Health J. 17:1222–1229. 2013. View Article : Google Scholar : | |
|
Kim HS, Yi BR, Hwang KA, Kim SU and Choi KC: Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells. Mol Cells. 36:347–354. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tammela T, Enholm B, Alitalo K and Paavonen K: The biology of vascular endothelial growth factors. Cardiovasc Res. 65:550–563. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kang NH, Yi BR, Lim SY, Hwang KA, Baek YS, Kang KS and Choi KC: Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int J Oncol. 40:2022–2028. 2012.PubMed/NCBI | |
|
Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y, Przylecki W, Carroll R, Black PM and Perides G: Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol. 8:119–126. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rachakatla RS, Marini F, Weiss ML, Tamura M and Troyer D: Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 14:828–835. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rachakatla RS, Pyle MM, Ayuzawa R, Edwards SM, Marini FC, Weiss ML, Tamura M and Troyer D: Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest. 26:662–670. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI | |
|
Larmonier N, Ghiringhelli F, Larmonier CB, Moutet M, Fromentin A, Baulot E, Solary E, Bonnotte B and Martin F: Freshly isolated bone marrow cells induce death of various carcinoma cell lines. Int J Cancer. 107:747–756. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung EB, Kim SU and Choi KC: Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse Models. Cancer Gene Ther. 19:412–419. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, et al: Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 25:100–106. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC III, Restel BH, Ozawa MG, Moya CA, Rangel R, et al: A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 125:385–398. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Phermthai T, Odglun Y, Julavijitphong S, Titapant V, Chuenwattana P, Vantanasiri C and Pattanapanyasat K: A novel method to derive amniotic fluid stem cells for therapeutic purposes. BMC Cell Biol. 11:792010. View Article : Google Scholar : PubMed/NCBI | |
|
Tamagawa T, Ishiwata I and Nakamura Y: Differentiation of human amniotic membrane cells into osteoblasts in vitro. Hum Cell. 18:191–195. 2005. View Article : Google Scholar | |
|
Zhang X, Chen X, Wang H and Liu S: Development of amniotic fluid-derived stem cell. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 22:864–868. 2008.In Chinese. PubMed/NCBI | |
|
Kucerova L, Poturnajova M, Tyciakova S and Matuskova M: Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase. Stem Cell Res. 8:247–258. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bi WL, Parysek LM, Warnick R and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther. 4:725–731. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG and Blaese RM: Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4:244–251. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao WH, Cheng JX, Shi PF and Huang JY: Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both in vitro and in vivo. Nan Fang Yi Ke Da Xue Xue Bao. 31:903–907. 2011.In Chinese. PubMed/NCBI | |
|
Roufosse CA, Direkze NC, Otto WR and Wright NA: Circulating mesenchymal stem cells. Int J Biochem Cell Biol. 36:585–597. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hu YL, Fu YH, Tabata Y and Gao JQ: Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. J Control Release. 147:154–162. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SU: Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev. 29:193–201. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yi BR, Hwang KA, Kim YB, Kim SU and Choi KC: Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP prostate cancer cells. Int J Mol Sci. 13:12519–12532. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yi BR, Kim SU, Kim YB, Lee HJ, Cho MH and Choi KC: Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. Oncol Rep. 27:1823–1828. 2012.PubMed/NCBI | |
|
Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU and Choi KC: Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol. 7:543–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ďuriniková E, Kučerová L and Matúšková M: Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy. Acta Virol. 58:1–13. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Matuskova M, Baranovicova L, Kozovska Z, Durinikova E, Pastorakova A, Hunakova L, Waczulikova I, Nencka R and Kucerova L: Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J Gene Med. 14:776–787. 2012. View Article : Google Scholar : PubMed/NCBI |
